Prot#CC-5013-MCL-001: A Phase II Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent, Lenalidomide (Revlimid®) in Patients with Mantle Cell NHL who Have Relapsed or Progressed After Treatment with Bortezomib or a

Project: Research project

Project Details

StatusFinished
Effective start/end date10/15/1010/15/13

Funding

  • Celgene Corporation (CC-5013-MCL-001)